Medicus Pharma Ltd. (NASDAQ:MDCX) just got a green light from regulators in the United Arab Emirates to start a Phase 2a clinical trial for its drug Teverelix in women with endometriosis. The clearance came from the Department of Health – Abu Dhabi on Friday, and it's a big deal for the company's push into precision medicine.
The trial, called PRECISION-E2, is designed to test Teverelix in women with moderate-to-severe symptomatic endometriosis. That's a condition that affects roughly 10% of reproductive-age women worldwide, and it's driven by estrogen, which makes it a target for drugs that block that hormone's effects.
What makes this trial interesting is that it's not just testing whether the drug works. It's also trying to figure out who it works best for. The company is aiming to build a genomics-guided precision medicine program, which means they want to use genetic information to identify patients most likely to respond to a long-acting GnRH antagonist like Teverelix.
PRECISION-E2 Trial Design And Dosages
Here's how the trial is set up: it's a prospective, randomized, placebo-controlled study that will enroll about 84 women across multiple sites in the UAE. Participants will be split evenly into four groups:
- 60 mg subcutaneous Teverelix
- 90 mg subcutaneous Teverelix
- 90 mg intramuscular Teverelix
- A subcutaneous placebo
So, they're testing two different doses and two different ways of delivering the drug, all against a placebo.
Primary Endpoints And Future Objectives
The main thing they're measuring is whether the drug can keep serum estradiol levels within a specific range, known as the Barbieri window (20 to 50 pg/mL), for at least 14 consecutive days. That's a key marker for whether the drug is effectively suppressing estrogen, which is what you want in endometriosis treatment.
But they're also looking at secondary endpoints like safety, pain reduction, quality of life, immunogenicity, pharmacokinetic parameters, and bone turnover biomarkers. So, they're getting a full picture of how the drug affects patients.
The bigger goal here is to combine clinical, pharmacodynamic, and genomic data to find potential treatment-response signatures. In plain English, they want to see if there are genetic markers that predict who will respond well to Teverelix. If they find any, those signatures would need to be confirmed in later trials before they could be used to guide patient selection. So, this is early-stage stuff, but it's a step toward more personalized treatment for endometriosis.
This isn't the only thing Medicus has going on. Earlier in July, the company got written feedback from the FDA and central Institutional Review Board approval, with some modifications, for an optimized Phase 2 study of Teverelix in men after a first episode of acute urinary retention. And just this month, the FDA completed its safety review of the company's Investigational New Drug application for SKNJCT-005 and issued a "Study May Proceed" letter. That means Medicus can start an NDA-enabling registrational Phase 2b study of SkinJect (D-MNA) 200 mcg in patients with Gorlin Syndrome who have multiple basal cell carcinomas.
Investors seemed to like the news. Medicus Pharma shares were up 9.03% at $0.28 during premarket trading on Friday, according to market data.
So, Medicus is pushing forward on multiple fronts, and this UAE trial is a key piece of their strategy to make endometriosis treatment more targeted. It's early days, but the approach is worth watching.
